To-date SphK1 and SphK2 isozymes and the S1PRs have been the major focus of new designer therapies [17] due to the increasing evidence that over-active SphK-S1P signaling is an important driver for many human cancers, as tabulated in Table 1. This evidence concerns the gene SPHK2 and cancer.